Completed PHASE3 INTERVENTIONAL NCT00130975

Candesartan in the Prevention of Relapsing Atrial Fibrillation

Sponsor: Asker & Baerum Hospital

Interventions Candesartan

Updated 5 times since 2017 Last updated: Jan 3, 2007 Started: Apr 30, 2001 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Atrial Fibrillation, this trial is completed. The trial is conducted by Asker & Baerum Hospital and has accumulated 5 data snapshots since 2001. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asker & Baerum Hospital
AstraZeneca
Helse Ost
Ullevaal University Hospital

Data source: Asker & Baerum Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway
• Rud, Norway